12 July 2023
CVS Group plc
("CVS" or the "Company")
Block Listing Interim Review and TVR Update
CVS, one of the UK's leading providers of integrated veterinary services, makes the following notification pursuant to Schedule Six of the AIM Rules for Companies regarding its existing block listing arrangements. References to securities are to the Company's ordinary shares of 0.2 pence each ("Ordinary Shares").
| Name of the company: | CVS Group plc
| |||
| Name of relevant scheme: | 1. CVS Group plc 2017-2020 Sharesave Scheme; 2. CVS Group plc 2018-2021 SAYE Sharesave Scheme; and 3. CVS Group SAYE Plan1 4. CVS Long Term Incentive Plan
| |||
| Period of return: | From: | 12 January 2023 | To: | 11 July 2023 |
| Balance of unallotted securities under scheme(s) from previous return: | 1. 230 2. 12,864 3. 236,142 4. Nil | |||
| Plus: The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for): | 1. Nil 2. Nil 3. Nil 4. 120,000 | |||
| Less: Number of securities issued / allotted under scheme(s) during period: | 1. 0 2. 0 3. 43,087 4. 3,704 | |||
| Equals: Balance under scheme(s) not yet issued / allotted at end of period: | 1. 230 2. 12,864 3. 199,633 4. 116,296 | |||
| Number and class of securities originally listed and the date of admission: | 1. 114,302 Ordinary Shares admitted on 11 January 2021 and 1,535 Ordinary Shares admitted on 1 September 2021 2. 296,069 Ordinary Shares admitted on 1 September 2021 3. 350,000 Ordinary Shares admitted on 30 December 2021 4. 120,000 Ordinary Shares admitted on 15 May 2023 | |||
[1] The Ordinary Shares reserved under the CVS Group SAYE block listing will satisfy the exercise of option awards under the Company's SAYE Plan that commenced in 2018, having been approved by shareholders in general meeting on 30 November 2017 (as previously announced on 22 December 2021).
Total Voting Rights
The number of securities that have been issued during the block listing review period stated above includes 43,087 new Ordinary Shares issued in connection with the exercise of employee share options under the CVS Group plc 2019-2023 SAYE Sharesave Scheme and 3,704 new Ordinary Shares issued in connection with the exercise of employee options under the CVS Long Term Incentive Plan 2017.
Following the issue of these new Ordinary Shares, which rank pari passu in all respects with the Company's existing Ordinary Shares, the Company has a total issued share capital of 71,427,191 Ordinary Shares, each carrying one voting right. The Company holds no Ordinary Shares in treasury so the total number of voting rights is therefore 71,427,191.
This figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest, or a change to their interest, in the Company under the FCA's Disclosure Guidance and Transparency Rules.
Contacts:
CVS Group plc via Camarco
Richard Fairman, CEO
Scott Morrison, Company Secretary
Peel Hunt LLP (Nominated Adviser & Broker) +44 (0)20 7418 8900
Adrian Trimmings / Michael Burke / Andrew Clark / Lalit Bose
Berenberg (Joint Broker) +44 (0)20 3207 7800
Toby Flaux / Ben Wright / Ciaran Walsh / Milo Bonser
Camarco (Financial PR)
Geoffrey Pelham-Lane +44 (0)7733 124 226
Ginny Pulbrook +44 (0)7961 315 138
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
